BridgeBio Pharma expands its research into neuromuscular disease to include Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) with new subsidiary ML Bio Solutions

09.05.2019

BridgeBio Pharma Announces Pricing of Its Initial Public Offering

06.26.2019

BridgeBio Pharma Announces Filing of Registration Statement for Proposed Initial Public Offering

05.24.2019

Eidos Therapeutics Initiates Attribute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

02.27.2019

Phoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

02.22.2019

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

01.23.2019

Eidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

01.02.2019

QED Therapeutics Announces a Collaboration with Foundation Medicine to Develop Companion Diagnostics for Infigratinib

12.10.2018

Eidos Therapeutics Appoints William Lis to Board of Directors

12.06.2018

PellePharm to Present at Piper Jaffray Healthcare Conference

11.21.2018

LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases

11.20.2018

Eidos Therapeutics to Present at Two Upcoming Investor Conferences

11.14.2018

BridgeBio Pharma LLC Signs Joint Collaboration Agreement with Cincinnati Children’s to Accelerate Development of Genetic Disease Therapeutics

11.12.2018

Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy

11.10.2018

Eidos Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

11.06.2018

Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results

10.29.2018

Eidos Therapeutics Receives Positive Opinion for Orphan Designation from the European Medicines Agency for AG10, a Potent Oral Stabilizer for the Treatment of Transthyretin Amyloidosis

10.26.2018

Data Published in Nature Communications Demonstrates CoA Therapeutics’ Potential to Treat Genetically Driven Pantothenate Kinase-Associated Neurodegeneration (PKAN)

10.23.2018

QED Therapeutics Presents Data for Infigratinib in Cholangiocarcinoma in Late Breaking Abstract at the European Society of Medical Oncology 2018 Congress

10.19.2018

PellePharm Presents Updated Data from Two Phase 2 Studies Demonstrating the Potential of Patidegib Topical Gel to Treat Basal Cell Carcinomas in Patients with Gorlin Syndrome and Patients with Non-Gorlin Sporadic BCCs

10.15.2018

news

Catch up on news from BridgeBio and our pipeline developments. Follow us on LinkedIn and Twitter to keep up with all of the latest news.

news archive

icon icon